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Abstract
Hedgehog signaling is often activated in tumors, yet it remains unclear how GLI2, a transcription 
factor activated by this pathway, acts as an oncogene. We show that GLI2 is a pleiotropic 
oncogene. Overexpression induces genomic instability and blocks differentiation, likely mediated 
in part by enhanced expression of the stem cell gene SOX2. GLI2 also induces TGFβ dependent 
transdifferentiation of foreskin and tongue, but not gingival fibroblasts into myofibroblasts, 
creating an environment permissive for invasion by keratinocytes, which are in various stages of 
differentiation having down regulated GLI2. Thus, up-regulated GLI2 expression is sufficient to 
induce a number of the acquired characteristics of tumor cells; however the stroma, in a tissue 
specific manner, determines whether certain GLI2 oncogenic traits are expressed.
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INTRODUCTION
Five-year survival for patients with oral SCC, at 40%, is among the worst of all sites in the 
body. While tobacco and alcohol are the major etiological agents, oral cancer commonly 
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occurs in patients without a history of exposure to these agents (Schmidt et al., 2004). Thus, 
there is a need for improved understanding of the alterations in genes or pathways that lead 
to this disease in order to develop better therapeutic approaches and methods for early 
detection or chemoprevention.
Genome-wide DNA copy number profiling of oral SCC revealed that they characteristically 
amplify narrow regions of the genome, often < 3 Mb (Snijders et al., 2005). Although these 
amplicons are rare, (occurring in < 5% of tumors), they are highly informative for several 
reasons; (1) the narrow regions they span often contain only a small number of genes, (2) the 
genes highlighted by the amplicons may play a significant role in a large number of tumors, 
because their expression may be altered by mechanisms other than amplification (Albertson 
et al., 2003), and (3) up-regulation of the driver oncogenes in amplicons is expected to be 
under positive selection at the time the tumor was resected, since amplified DNA is unstable 
(Miele et al., 1989; Murnane & Sabatier, 2004; Roth & Andersson, 2004; Shimizu et al., 
2005) and would otherwise disappear. Amplicons in oral SCC implicated alterations in 
integrin signaling, apoptosis, adhesion and migration, as well as deregulation of the 
hedgehog and notch pathways (Snijders et al., 2005).
Whereas genome-wide profiling of tumors highlights candidate disease genes, identifying 
the critical ones and how they promote tumor development remains difficult. To evaluate the 
role of GLI2, a gene mapping to one of the narrow amplicons in oral SCC, we co-cultured 
keratinocytes overexpressing GLI2 with fibroblasts in three dimensional organotypic 
cultures to allow communication between cell types and differentiation of the epithelium 
(Bell et al., 1981). GLI2 is a member of the GLI family of transcription factors, activated by 
hedgehog signaling. In the canonical pathway, a hedgehog ligand (e.g. sonic hedgehog, 
SHH) binds the transmembrane receptor Patched (PTCH1), which in turn relieves inhibition 
of a second transmembrane protein Smoothened (SMO) resulting in activation of the GLI 
transcription factors. Abnormal activation of the hedgehog pathway has been implicated in a 
variety of cancers, occurring either via the canonical pathway or by activation downstream 
of SMO (Lauth & Toftgard, 2007). In oral SCC, GLI2 is up-regulated both in tumors with 
amplification and also in a subset of oral SCC (~25%) without amplification. When 
overexpressed, GLI2 is biologically active in these tumors as evidenced by up-regulation of 
GLI1 and PTCH1, known targets of GLI2 (Snijders et al., 2005). Here, we report that 
overexpression of GLI2 promotes a number of the acquired characteristics of tumor cells 
that constitute the cancer phenotype.
RESULTS
Tumors with GLI2 amplification show basal-like cellular histology
Oral SCC with high level amplification of GLI2 (Figures 1A and B) display basal-like 
histology in routine hematoxylin and eosin (H&E) stained sections (Figures 1C and D), 
suggesting that GLI2 overexpression inhibits differentiation. In other aspects of histology, 
however, the tumors differed markedly. In addition, the genomic copy number profiles of 
the GLI2 amplifying tumors differed (Figure 1E), suggesting that amplification of GLI2 does 
not dictate the aberration spectrum in these tumors.
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Overexpression of GLI2 in keratinocytes in monolayer cultures does not provide a growth 
advantage
GLI2 acts both as a transcriptional activator and repressor. Therefore, to study the functional 
consequences of GLI2 up-regulation on cell growth and differentiation, we obtained 
tetracycline-inducible HaCaT cells expressing a constitutively active form of GLI2 (6xHis-
GLI2ΔN), which lacks the N-terminal repressor domain (hereafter referred to as HaCaT 
GLI2) and control tetracycline responsive HaCaT cells lacking the GLI2ΔN expression 
construct (hereafter referred to as HaCaT Tet) from Dr. F. Aberger (Regl et al., 2004). The 
parental HaCaT cells have mutations in both TP53 alleles and cytogenetically abnormal, but 
stable karyotypes (Boukamp et al., 1988). Nevertheless, they retain the capability to 
differentiate in organotypic cultures and have been used extensively as a substitute for 
normal human keratinocytes (Schoop et al., 1999). Previous genome-wide expression 
profiling demonstrated that HaCaT cells and primary keratinocytes respond in a similar 
fashion to forced GLI expression (Regl et al., 2004). We confirmed that doxycycline 
induced high levels of expression of GLI2 and downstream targets, GLI1 and PTCH1, in 
HaCaT GLI2 cells in monolayer culture (Supplementary Figure 1A). We observed a 
reduction in proliferation in these cells (Supplementary Figure 1B), that was not due to an 
increased rate of apoptosis, as measured by the percentage Annexin V positive cells (data 
not shown). Similar results were obtained when we infected independent cultures of HaCaT 
cells with a 6xHis-GLI2ΔN retrovirus (Supplementary Figure 1C). We also found a dramatic 
reduction in the colony-forming efficiency of GLI2 expressing HaCaT GLI2 cells plated at 
low density (Supplementary Table 1). Allowing the HaCaT GLI2 cells to attach for 48 hours 
prior to inducing GLI2 expression did not significantly increase the number of colonies 
(Supplementary Table 1). Thus, overexpression of GLI2 in HaCaT cells in monolayer 
culture confers no growth advantage as measured by enhanced proliferation rate or capacity 
for autonomous growth. On the other hand, senescence and/or poor attachment of the GLI2 
expressing cells to the substrate may be contributing to the reduced rate of increase in cell 
number (see below).
Overexpression of GLI2 induces genomic instability
Enhanced expression of oncogenes can lead to replication stress, up-regulation of the DNA 
damage response and genomic instability (Bartkova et al., 2005; Gorgoulis et al., 2005). To 
determine whether overexpression of GLI2 induces genomic instability, we asked whether 
GLI2 expression enhanced formation of methotrexate resistant colonies in HT1080, a cell 
line that reportedly does not give rise to methotrexate resistant colonies without prior 
exposure to a DNA damaging agent (Paulson et al., 1998). We generated HT1080 variants 
(see Supplementary Methods) expressing 6xHis-GLI2ΔN, enhanced green fluorescent 
protein (eGFP) and CCND1, an oncogene known to induce genomic instability in vitro 
(Nelsen et al., 2005; Zhou et al., 1996) and to be up-regulated prior to amplification in vivo 
in head and neck cancer (Izzo et al., 1998; Roh et al., 2000). Upon challenge with 25 nM 
methotrexate (2–3 × LD50), the GLI2 and CCND1 expressing HT1080 cells gave rise to 
equal numbers of drug resistant colonies and these numbers were significantly greater than 
the number recovered from either eGFP expressing or parental HT1080 cells 
(Supplementary Figures 2A and B), indicating that GLI2 overexpression like CCND1 
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overexpression induces genomic instability. We have shown previously that increased 
numbers or specific types of genomic alterations may be acquired by methotrexate resistant 
cells depending on genetic background (Snijders et al., 2003; Snijders et al., 2008). No 
specific types of chromosomal level instability were evident by array CGH in the 
methotrexate resistant cells overexpressing GLI2 (Supplementary Figure 2C). Similarly, we 
did not observe enhanced DNA breakage in GLI2 expressing cells as measured by the comet 
assay (data not shown). Thus, extensive DNA damage does not appear to occur in GLI2 
overexpressing cells. At this time the mechanism of GLI2 induced genomic instability 
remains unknown.
Overexpression of GLI2 in keratinocytes in organotypic cultures recapitulates tumor 
histology
To assess the effects of GLI2 overexpession on differentiation, we cultured GLI2 expressing 
and control cells (HaCaT Tet and uninduced HaCaT GLI2 cells) with dermal fibroblasts in 
three dimensional organotypic cultures. In cultures with GLI2 expressing HaCaT GLI2 cells, 
we observed gross differences compared to controls. The epithelial layer of the GLI2 
expressing tissue reconstructs adhered poorly to the collagen/fibroblast layer during routine 
tissue processing and there was a decrease in fibroblast surface area compared to controls 
(Supplementary Figure 3). These observations suggest that GLI2 expression reduced 
adhesive interactions between the epithelium and extracellular matrix and induced increased 
contraction of the collagen gel by the fibroblasts.
In routine H&E stained sections, GLI2 expressing HaCaT cells appeared basal-like (Figure 
2A), recapitulating the histopathology of oral SCC with GLI2 amplification. We found both 
a decrease in keratinocyte nuclear size upon induction of GLI2 and an increase in nuclear 
density compared to controls (Supplementary Table 2). In addition, fibroblasts in the upper 
region of the dermal layer appeared less spindle shaped. Antibodies for pancytokeratin 
uniformly stained the epithelial layer in all reconstructs, and revealed the presence of 
individual or small groups of positively stained cells invading into the upper region of the 
collagen/fibroblast layer of GLI2 expressing HaCaT GLI2 reconstructs (Figure 2B).
GLI2 overexpression does not accelerate proliferation in organotypic cultures
We investigated whether expression of GLI2 promoted proliferation by staining tissue 
reconstructs for proliferation (Ki67) and mitotic (phosphohistone H3, PHH3) markers. In 
GLI2 expressing HaCaT GLI2 reconstructs, staining was present throughout the entire 
epidermis, as well as in fibroblasts in the upper portion of the collagen/fibroblast layer, in 
stark contrast to the limited expression in only a few cells in the basal layer of the epidermis 
in controls (Figure 2C and Supplementary Figure 4). Although the proportion of Ki67 
positive keratinocytes in induced HaCaT GLI2 organotypic cultufres was greater than in 
controls, no differences in the ratio of mitotic cells (PHH3 positive) to cycling Ki67 positive 
cells (Supplementary Table 3) were found for any pairwise comparison of the three cell 
types (Wilcoxon rank sum test). Thus, while cells overexpressing GLI2 are inappropriately 
in cycle in all layers of the epithelium, GLI2 overexpression does not promote more rapid 
cycling.
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Overexpression of GLI2 opposes differentiation and impairs formation of a basement 
membrane zone
The basal-like phenotype of GLI2 expressing cells in the organotypic cultures and in the 
GLI2 amplifying tumors suggests that GLI2 opposes differentiation. Therefore, we stained 
sections from tissue reconstructs comprised of dermal fibroblasts and normal keratinocytes, 
control cells (HaCaT Tet and uninduced HaCaT GLI2 cells) and GLI2 expressing HaCaT 
GLI2 cells for differentiation markers cytokeratin 10/13 (CK10/13), involucrin and loricrin 
(Figure 3 and Supplementary Figure 4). Whereas staining for these markers was observed in 
the upper, more differentiated layers of the epidermis formed in reconstructs of normal 
dermal keratinocytes and controls, in GLI2 expressing reconstructs only sparse individual 
cells stained positively for CK10/13 or involucrin, but not for loricrin. We also observed that 
the invasive cells in the GLI2 expressing reconstructs stained positively for CK10/13 and in 
some cases for involucrin, but not loricrin (Figure 3).
Expression of components of the basement membrane zone in GLI2 expressing HaCaT 
GLI2 cells was also abnormal (Figure 3D–F and Supplementary Figure 4). Integrin β4 
(ITGB4), which participates in formation of hemi-desmosomes anchoring the epithelium to 
the stroma, was observed at the basal side of the basal keratinocyte layer in a linear pattern 
in controls, but was absent in GLI2 expressing HaCaT GLI2 reconstructs. Similarly, laminin 
5 gamma-2 subunit (LAMC2) was only present in a few cells and not limited to the basal 
layer, whereas staining was intense in the cytoplasm of keratinocytes in the basal layer and 
at the dermal epidermal junction (DEJ) in controls. We also observed that ITGB4 or 
LAMC2 staining was present in some of the invading keratinocytes in the GLI2 expressing 
reconstructs. These observations and the poor adhesion of the GLI2 expressing HaCaT GLI2 
cells to the collagen/fibroblast layer of the tissue reconstructs suggest that GLI2 
overexpression causes defects in the structural link between the GLI2 expressing 
keratinocytes and the extracellular matrix. Indeed, in tissue reconstructs prepared from 
dermal fibroblasts and 1:1 mixtures of GLI2 expressing HaCaT GLI2 cells and control 
HaCaT Tet cells, we observed that the GLI2 expressing cells were exclusively located in the 
upper half of the epidermis, while control cells occupied the lower half (Figure 4).
Abnormal expression of collagen IV (COL4) was also present in GLI2 expressing HaCaT 
GLI2 reconstructs. In contrast to the continuous band of staining at the DEJ in normal 
keratinocytes and control HaCaT reconstructs (Figure 3F and Supplementary Figure 4), 
intense COL4 staining extended throughout the upper quarter to one-third of the collagen/
fibroblast layer, encompassing several cell layers and appeared co-extant with the layer of 
more spindle shaped fibroblasts seen in the H&E stained sections (Figure 2A). Thus, 
overexpression of GLI2 both blocks differentiation and disrupts the normal expression 
pattern of keratinocyte derived proteins linking the epithelium to the stroma.
GLI2 induces expression of stem cell genes in keratinocytes
Stem cell gene expression signatures have been reported in poorly differentiated breast and 
other tumors (Ben-Porath et al., 2008; Chen et al., 2008), as well as in gliomas, which are 
associated with activated hedgehog signaling and GLI overexpression (Clement et al., 
2007), suggesting that GLI2 might block keratinocyte differentiation by up-regulating stem 
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cell genes. To investigate this possibility, expression profiling was carried on RNA extracted 
from isolated keratinocyte layers from the tissue reconstructs. This analysis revealed 
elevated expression of SOX2 in the GLI2 expressing keratinocytes (Supplementary Figure 
5), which was also confirmed by staining reconstructs with antibodies to SOX2 (Figure 5). 
These observations suggest that SOX2 is a GLI2 responsive gene. Indeed, infection of 
primary keratinocytes with a GLI2 retrovirus resulted in induction of SOX2 RNA 
(Supplementary Figure 6A), and in HaCaT GLI2 cells, addition of doxcycline induced SOX2 
expression with the same kinetics as the two known GLI2 downstream targets, GLI1 and 
PTCH1 (Supplementary Figure 6B). Moreover, a number of potential GLI2 consensus 
binding sites are present in SOX2 (Supplementary Table 4). In a separate analysis, we found 
that neither NANOG nor OCT4 (POU5F1) was up-regulated in GLI2 expressing cells (data 
not shown), whereas elevated RNA and protein expression of TITF1 (Nkx2.1) was observed 
(Figure 5). TITF1 is reciprocally regulated with SOX2 during early dorsal/ventral foregut 
patterning (Que et al., 2007). It is frequently amplified in lung cancer (Kendall et al., 2007; 
Kwei et al., 2008; Weir et al., 2007) and was amplified in one of 89 oral SCC (Snijders et 
al., 2005). Thus, induction of stem cell genes is likely to underlie the block in differentiation 
resulting from GLI2 overexpression, and is consistent with disruption of differentiation 
when SOX2 is expressed at high levels in basal epithelial cells of transgenic mice (Okubo et 
al., 2006).
Overexpression of GLI2 induces differentiation of fibroblasts into myofibroblasts
Alterations in cells in the upper region of the collagen/fibroblast layer of the tissue 
reconstructs expressing GLI2 are reminiscent of the desmoplastic response of the stroma 
adjacent to many tumors, wherein stromal cells display, among other characteristics, 
myofibroblastic features, including up-regulated synthesis of α smooth muscle actin (SMA), 
and increased proliferation, contractility and deposition of collagen. The myofibroblastic 
carcinoma associated fibroblasts (CAFs) may be derived from a variety of cell types in vivo 
(De Wever & Mareel, 2003; Kalluri & Zeisberg, 2006; Mueller & Fusenig, 2004; Zeisberg 
et al., 2007). Since expression of SMA is one of the hallmarks of CAFs, we assessed SMA 
expression and observed positive staining at the DEJ of tissue reconstructs prepared from 
dermal fibroblasts and normal dermal keratinocytes or control HaCaT Tet cells (Figure 6B 
and Supplementary Figure 4). By contrast in reconstructs prepared with HaCaT GLI2 cells 
expressing GLI2 and eGFP, we observed intense positive SMA staining in cells in the same 
upper region of the collagen/fibroblast layer that was also positive for collagen IV (Figure 
6B). Moreover, no SMA positive cells also expressed eGFP (Figure 6B), indicating that the 
myofibroblasts originated from the co-cultured dermal fibroblasts and not from 
keratinocytes that had undergone epithelial to mesenchymal transition. Since our study of 
GLI2 was motivated by the observation of GLI2 amplification in oral SCC, we also prepared 
reconstructs with fibroblasts cultured from tongue and gingiva. Whereas, GLI2 expressing 
HaCaT GLI2 cells induced transdifferentiation of tongue fibroblasts in organotypic cultures, 
no transdifferentiation was observed with cultures of gingival fibroblasts (Figure 6C).
These observations predict that SMA expression should be present in oral SCC with GLI2 
amplification. This expectation was confirmed, as we observed high levels of expression of 
SMA adjacent to tumor cell islands in oral SCC with GLI2 amplification (Figure S7). We 
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note, however, that SMA positive stroma is not restricted to tumors with GLI2 amplification, 
as we found 44% of oral SCC (11/25) from different oral subsites including gingiva to stain 
positively, while normal oral tissues, hyperkeratosis, and pre-malignant lesions (various 
grades of dysplasia and proliferative verrucous leukoplakia) were all negative, in agreement 
with other reports (Kellermann et al., 2007; Lewis et al., 2004).
GLI2 induced myofibroblast differentiation requires TGFβ signaling
Signaling via TGFβ has been implicated in promoting fibrosis and differentiation of 
fibroblasts into myofibroblasts in tumor associated desmoplasia (De Wever & Mareel, 2003; 
Tuxhorn et al., 2001). To determine whether TGFβ signaling underlies the phenotypes 
observed in the GLI2 expressing HaCaT organotypic cultures, we treated these cultures with 
the TGFβRI/II kinase inhibitor LY2109761 (Lacher et al., 2006) or DMSO. Both the 
LY2109761 and control, DMSO treated cultures displayed the basal-like epithelial cells 
characteristic of GLI2 expressing HaCaT GLI2 cultures, as well as similar proportions of 
Ki67 and PHH3 positive nuclei (0.85–0.88 and 0.24–0.29, respectively). In the dermal layer 
of the LY2109761 treated cultures, however, we observed noeither differentiation of 
fibroblasts into myofibroblasts nor keratinocyte invasion (Figure 6D). We obtained similar 
results when TGFβ signaling was abrogated in foreskin fibroblasts by introduction of a 
dominant negative TGFβ type II receptor construct lacking the kinase domain (Verona et al., 
2007) (data not shown) or when the keratinocyte and fibroblast layers were separated by a 
20–40 µm thick layer of acellular collagen (Supplementary Figure 8). Thus, TGFβ signaling 
in fibroblasts is required for their transdifferentiation and generation of a stromal 
environment permissive for invasion.
Invading keratinocytes down regulate GLI2 responsive genes and are only locally invasive 
within the myofibroblast modified collagen matrix
Transdifferentiation of stromal myofibroblasts via TGFβ1 is also associated with up-
regulated secretion of HGF, which acts in a paracrine manner to activate its receptor, c-Met 
on keratinocytes by inducing its autophosphorylation. Activation of MET results in 
enhanced proliferation, motility and invasiveness of keratinocytes. We confirmed that HGF 
transcription was up-regulated in GLI2 expressing HaCaT GLI2 reconstructs (data not 
shown). In addition, the GLI2 expressing HaCaT GLI2 cells in the tissue reconstructs 
stained positively for both c-Met and phosphorylated c-Met, whereas control HaCaT Tet 
cells were only positive for c-Met (Figures 7A and B). Thus, c-Met signaling is activated in 
the GLI2 expressing cells with the potential to induce keratinocyte migration and invasion.
All keratinocytes invading into the collagen/fibroblast layer of GLI2 expressing HaCaT 
GLI2 tissue reconstructs appeared to be positive for pancytokeratin (Figure 2C) and were 
uniformly negative for E-cadherin (Figure 7C), while cells in the epithelial layer showed 
membranous staining for both E-cadherin and β-catenin (Figure 7D), suggesting that 
invasion is dependent on the loss of E-cadherin as is commonly observed in other systems. 
Enhanced expression of β-catenin was also noted in the myofibroblasts in GLI2 expressing 
HaCaT GLI2 reconstructs. It was notable that the invading cells down regulated expression 
of the GLI2 responsive gene BCL2 (Figures 7E and Supplementary Figure 9), as well as 
SOX2 and TITF1 (Figure 4), and some cells stained positively for differentiation markers 
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(Figure 3) or markers of apoptosis (caspase 3 or TUNEL, Figure 7F and data not shown). 
We also observed a lack of sprouting from spheroids formed from GLI2 expressing HaCaT 
GLI2 cells embedded in collagen I matrices (Figure 8). These observations suggest that 
GLI2 expressing keratinocytes are non-invasive and that the capabilities to both invade and 
differentiate are acquired upon down regulation of GLI2. Nevertheless, invading cells appear 
to remain confined to the myofibroblast region. These observations together with the lack of 
invasion in tissue reconstructs lacking myofibroblasts (e.g. due to inhibition of TGFβ1 
signaling) suggest that remodeling of the collagen I matrix by myofibroblasts is required for 
local invasion of HaCaT GLI2 cells that have down regulated GLI2 responsive genes.
DISCUSSION
We have shown that GLI2 is a pleiotropic oncogene, and thus, up-regulated GLI2 expression 
alone is sufficient to induce a number of the hallmarks of cancer (Hanahan & Weinberg, 
2000). Nevertheless, the differential responses of fibroblasts to GLI2 overexpressing 
keratinocytes indicate that the stroma, in a tissue specific manner, determines whether 
certain GLI2 oncogenic traits are expressed.
The roles of other oncogenes have been evaluated in HaCaT organotypic cultures, including 
HRAS, BCL2 (Delehedde et al., 2001), MYC, TERT (Cerezo et al., 2003), CCND1 
(Burnworth et al., 2006), and SHH (Bigelow et al., 2005). While expression of the GLI2 
target, BCL2 had little effect on differentiation, expression of other genes resulted in 
phenotypes shared with GLI2, including extension of proliferating Ki67 positive cells from 
the basal layer to upper epithelial layers (CCND1, HRAS, SHH) and absence or abnormal 
expression of differentiation markers (TERT, CCND1). The absence of the basement 
membrane zone, however, may be unique to the GLI2 phenotype as its formation was 
reported to be normal in HaCaT reconstructs overexpressing TERT, MYC or CCND1.
Modification of fibroblasts and keratinocyte invasion have been reported in organotypic 
cultures of SHH expressing HaCaT cells (Bigelow et al., 2005) and GLI2 overexpressing 
hTERT immortalized keratinocytes (Marsh et al., 2008). In contrast to our studies, however, 
invasion occurred as fingers of cells rather than as individual cells or small groups of cells. 
On the one hand, although SHH and GLI2 are the proximal and distal ends of the hedgehog 
pathway, the different phenotypes may be attributed to the fact that additional signaling 
pathways are induced by SHH expression (Riobo et al., 2006) or by differences in the level 
of GLI2 expression, considered a critical determinant of the outcome of hedgehog signaling 
(Grachtchouk et al., 2003; Hooper & Scott, 2005; Riobo et al., 2006). On the other hand, the 
differences in invasive phenotype may be attributed to the source of fibroblasts used in the 
organotypic cultures. Embryonic (NIH3T3) or human fetal foreskin fibroblasts were used to 
prepare the organotypic cultures with SHH expressing HaCaT cells and GLI2 
overexpressing hTERT immortalized keratinocytes, respectively. It is well recognized that 
fetal wounds heal without scarring, suggesting that the different patterns of invasion 
observed in response to activation of the hedgehog pathway may reflect tissue specific 
behavior of fibroblasts. In our studies, the differential response of fibroblasts to TGFβ1 may 
be attributed to the embryological origins of the cells (e.g. neural crest and pharyngeal 
arches, gingival and tongue, respectively), repertoire of genes expressed (Chang et al., 
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2002), and signaling pathways involved in inducing SMA expression in response to TGFβ1 
(Black et al., 2007). While further work is required to dissect the different signaling 
pathways and responsiveness of dermal, tongue and gingival fibroblasts to TGFβ1, these 
studies, in accord with Paget’s “seed and soil” hypothesis, highlight the importance of co-
evolution of carcinoma cells and stroma, and the importance of the stroma in determining 
the invasive properties of the tumor.
The oncogenic properties of GLI2 revealed in organotypic cultures are directly relevant to 
the behavior of tumors in vivo. The cultures recapitulated the basal-like histology of the 
GLI2 amplifying tumors and correctly predicted that SMA positive cells should be present in 
the stroma of these tumors. These studies also revealed that invasive keratinocytes had down 
regulated GLI2 responsive genes, which may have been necessary to overcome GLI 
promoted cell-cell adhesion (Neill et al., 2008); however concomitant with reduction in 
GLI2 expression is the apparent release of the block in the differentiation program, allowing 
the cells to differentiate and die. These cells are likely to be inefficient at seeding 
metastases, consistent with the low frequency of metastasis associated with basal cell 
carcinomas (BCC), a GLI2 overexpressing skin tumor. Phenotypic differences in invasive 
cells of BCCs have been noted previously (Svensson et al., 2003). Thus, the organotypic 
culture model allows specific oncogene associated molecular alterations to be identified in 
both the carcinoma and the stroma. In the case of GLI2 amplifying or overexpressing 
tumors, phenotypes observed in the organotypic cultures suggest that benefit could be 
gained from therapeutic approaches targeting both the consequences of GLI2 overexpression 
in the carcinoma cells, as well as TGFβ signaling in the stroma, for which a number of 
agents have already been identified (De Wever & Mareel, 2003; Lauth et al., 2007; Mueller 
& Fusenig, 2004).
MATERIALS AND METHODS
Establishment of primary keratinocyte and fibroblast cultures
Human neonatal foreskin tissue was obtained from the UCSF Well Baby Nursery following 
UCSF guidelines for obtaining and handling human tissue. Human oral tissues were 
obtained from patients undergoing routine third molar extraction at the UCSF Dental Clinic 
or were obtained from clinically normal tissue at the time of surgical excision of dysplasia or 
SCC in the UCSF Department of Oral and Maxillofacial Surgery. Patients ranged in age 
from 17 to 43. Only discarded tissue was used and all identifiers were removed from the 
samples prior to collection. Epithelial keratinocyte and fibroblasts cultures were prepared 
and maintained as described in the Supplementary Methods.
Cell culture
All HT1080 and HaCaT cells were cultured in DME H-16 supplemented with 10% fetal calf 
serum at 37°C in 5% CO2 unless otherwise specified. Cells transfected with various 
constructs were cultured in the presence of appropriate antibiotics as described in the 
Supplementary Methods.
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Organotypic cultures were prepared by adding oral or dermal fibroblasts (7.5 × 104) to 
collagen, plating them in 6-well culture plates and culturing for 48 hours to allow the gel to 
contract before adding 5 × 105 keratinocytes to the surface. After 48–72 hours, the cultures 
were raised to the air/liquid interface and the rafts cultured for a further 2–3 weeks, after 
which time they were fixed and processed for routine histology as described in detail in the 
Supplementary Methods.
Immunohistochemistry and Immunofluorescence
Sections were deparaffinized by three five minute washes in xylene, followed by two 
washes for five minutes each through a graded alcohol series to distilled water. Different 
antigen retrieval methods and processing for immunohistochemistry and 
immunofluorescence were used as appropriate for each antibody (Supplementary Tables 5 
and 6).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Tumors with GLI2 amplification display basal-like cellular histology, while also 
displaying tumor-specific histologic and genomic aberrations
(A and B) Normalized genomic DNA copy number profiles for chromosome 2 from oral 
SCC showing high level amplification of the GLI2 locus. The tongue oral SCC 6929 was 
obtained from the UCSF Oral Cancer Tissue Bank, which collects and archives oral tissue 
samples after obtaining patient consent according to UCSF Institutional Review Board 
guidelines. The anterior floor of mouth oral SCC 1300C2 was provided by Drs. Gillian Hall 
and Richard Shaw, School of Cancer Studies, University of Liverpool, UK and was 
collected under approved procedures of that institution. Tumor DNA was extracted from 
formalin fixed paraffin embedded tissue sections following micro-dissection of tumor 
islands and subjected to BAC array CGH analysis according to our standard protocols 
(Snijders et al., 2005). The array CGH analysis of oral SCC 6929 was reported previously 
(Snijders et al., 2005).
(C and D) H&E stained sections of the GLI2 amplifying tumors. The tumor cells are small 
with hyperchromatic nuclei and scant cytoplasm. Keratinization is absent. In SCC 1300C2, 
mitotic figures are abundant (6.3 ± 2.5 mitotic figures per high power field) and comedo 
necrosis is present at the centers of the tumor islands, features which are absent in SCC 
6929.
Snijders et al. Page 13
Oncogene. Author manuscript; available in PMC 2009 August 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(E) Heatmap representation of copy number changes detected by array CGH in GLI2 
amplifying tumors. Each column represents one tumor. Individual BAC clones are shown as 
rows and ordered according to their genome position (May 2004 freeze, UCSC Genome 
Browser). Copy number aberrations were assigned as described previously (Fridlyand et al., 
2006). Losses are indicated in red, gains in green and amplifications as yellow dots.
Snijders et al. Page 14
Oncogene. Author manuscript; available in PMC 2009 August 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. Characteristics of control and HaCaT GLI2 organotypic cultures
Sections of organotypic cultures of control HaCaT Tet (left), uninduced HaCaT GLI2 
(middle) and induced HaCaT GLI2 cells (right) stained with H&E (A) or stained using horse 
radish peroxidase (HRP) and diaminobenzidine (DAB) detection and antibodies to epithelial 
cell specific pan-cytokeratin (Cam5.2 & AE1/AE3 (B), Ki67 (C) and PHH3 (D).
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Figure 3. GLI2 blocks epithelial differentiation and impairs formation of the basement 
membrane zone
Sections of organotypic cultures of HaCaT Tet control (left), uninduced HaCaT GLI2 
(middle) and induced HaCaT GLI2 cells (right) stained using HRP and DAB detection and 
antibodies to keratinocyte differentiation markers, cytokeratin 10/13 (A), involucrin (B), 
loricrin (C), and basement membrane components laminin 5 gamma-2 subunit (D), integrin 
β4 (E) and collagen type IV (F).
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Figure 4. GLI2 expressing cells grown in the presence of control HaCaT Tet cells fail to adhere to 
the collagen/fibroblast layer
Frozen sections of organotypic cultures prepared with 1:1 mixtures of control HaCaT Tet 
cells and HaCaT GLI2 cells infected with lentiviruses expressing eGFP (green) or RFP 
(red), respectively and grown in the absence or presence of doxycycline. Nuclei 
counterstained by DAPI are shown in blue.
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Figure 5. GLI2 induces expression of stem cell genes
Sections of organotypic cultures of GLI2 expressing HaCaT GLI2 cells stained using HRP 
and DAB detection and antibodies to SOX2 and TITF1. The locations of keratinocytes in the 
sections are indicated by staining adjacent sections with antibodies to CAM5.2. Two 
photomicrographs are shown from each section.
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Figure 6. GLI2 induces TGFβ mediated differentiation of fibroblasts into myofibroblasts
(A) Increased Ki67 staining in stromal fibroblasts in GLI2 expressing reconstructs. 
Immunofluorescent staining for Ki67 (red) in control HaCaT Tet reconstructs (left panel) 
and in GLI2 and eGFP expressing HaCaT GLI2 reconstructs (right panel). In GLI2 
expressing reconstructs, most cells in the epithelial layer are positive for both Ki67 and 
eGFP, confirming their epithelial origin. In the stromal compartment of GLI2 expressing 
reconstructs, the majority of Kig positive cells do not co-express eGFP confirming their 
fibroblast origin.
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(B) Staining for SMA is limited to the uppermost region in the dermal compartment, directly 
underneath the DEJe, which is demarcated by integrin β4 co-staining (green) in HaCaT Tet 
reconstructs (left panel). Intense SMA staining is present in the upper dermal compartment 
of reconstructs from GLI2 and eGFP expressing HaCaT GLI2 cells (right panel), which are 
also stained for GFP (green). No SMA positive cells co-expressed GFP.
(C) Organotypic cultures comprised of oral fibroblasts and HaCaT Tet (left) or GLI2 
expressing HaCaT GLI2 cells (right) stained for SMA (brown, HRP and DAB detection) 
and counterstained with hematoxylin (blue). Cultures were prepared with tongue or gingival 
fibroblasts at passage 2 (top and bottom panels, respectively).
(D) GLI2-induced myofibroblast differentiation is dependent on active TGFβ signaling. 
Organotypic cultures from HaCaT GLI2 cells expressing GLI2 and eGFP were treated with 
either DMSO (left panels) or with the TGFβRI/II kinase inhibitor LY2109761 dissolved in 
DMSO at 2 µM (right panels). Sections were stained with H&E (upper panels) and for SMA 
and eGFP (bottom panels). The epithelial layer appears thinner in the drug treated sections 
due to less contraction of the collagen gel, which normally reduces the area covered by the 
GLI2 expressing HaCaT GLI2 cells.
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Figure 7. Invading epithelial cells in GLI2 expressing tissue reconstructs express keratinocyte 
differentiation markers and down regulate GLI2 responsive genes
Sections of organotypic cultures of control HaCaT Tet (left) and induced HaCaT GLI2 cells 
(right) were stained using immunohistochemistry or immunofluorescence with antibodies 
for (A) c-Met, (B) phosphorylated c-Met, (C) E-cadherin, (D) β-catenin, (E) BCL2 and (F) 
the apoptosis marker caspase 3 (green) and epithelial marker pan-cytokeratin (CAM5.2 and 
AE1/AE3, red). Nuclei were counterstained with hematoxylin (immunohistochemistry) or 
DAPI (immunofluorescence) and are shown in blue.
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Figure 8. GLI2 expressing HaCaT cells do not migrate into collagen I gels
Spheroid cultures of eGFP expressing control HaCaT Tet cells (green), RFP expressing 
HaCaT GLI2 cells (red) and a 1:1 mixture of eGFP expressing HaCaT Tet cells (green) and 
RFP expressing HaCaT GLI2 cells (red) were embedded in a collagen I matrix and grown 
for 13 days with or without doxycycline to induce GLI2 expression.
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